Novartis and Malaria No More, a global charity aiming to end malaria deaths, are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria.
Over the next three years, Novartis will support the campaign financially and also donate up to 3-million full courses of its pediatric anti-malarial drug to match the treatments donated by the public, doubling the impact of these donations.
“We believe that this innovative campaign will help speed malaria elimination,” says Joseph Jimenez, Novartis CEO.
“Novartis has been striving towards this goal for more than a decade, and we just reached the milestone of providing 600-million treatments without profit to patients in malaria-endemic countries. No one should die from malaria today.”
Malaria is a preventable and treatable disease, yet a child dies from malaria every minute. This against a backdrop of global funding gaps and concern that the gains made to defeat the disease could be reversed. The Power of One campaign aims to address this need by closing the global treatment gap between now and the end of 2015 through direct donations and existing government commitments.
“The Power of One campaign challenges the global public to help close the global treatment gap for malaria; every dollar raised will buy and deliver a full course of life-saving child treatment,” says Martin Edlund, CEO of Malaria No More.
“We are delighted to be partnering with forward-thinking companies like Novartis to help end deaths from this disease – one dollar and one child at a time.”